C. Sommerer

发表

Everolimus in patients with autosomal dominant polycystic kidney disease.

Martin Büchert, Kai-Uwe Eckardt, Klemens Budde, 2010, The New England journal of medicine.

Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation

K. Budde, C. Sommerer, O. Rissling, 2016, Therapeutic drug monitoring.

Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats.

C. Sommerer, M. Zeier, M. Gross, 2009, American journal of physiology. Renal physiology.

Cardiac Biomarkers in Haemodialysis Patients: The Prognostic Value of Amino-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin T

C. Sommerer, M. Zeier, E. Giannitsis, 2007, Nephron Clinical Practice.

Cardiac biomarkers and survival in haemodialysis patients

H. Katus, C. Sommerer, M. Zeier, 2007, European journal of clinical investigation.

Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report

U. Christians, H. Colom, V. Haufroid, 2019, Therapeutic drug monitoring.

Assessment of renal allograft fibrosis by transient elastography

S. Mueller, C. Sommerer, M. Zeier, 2013, Transplant international : official journal of the European Society for Organ Transplantation.

Nuclear Factor of Activated T Cells–Regulated Gene Expression as Predictive Biomarker of Personal Response to Calcineurin Inhibitors

T. Giese, C. Sommerer, 2016, Therapeutic drug monitoring.

Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation

U. Christians, V. Haufroid, P. Marquet, 2016, Therapeutic drug monitoring.

Calcineurin inhibitors and NFAT-regulated gene expression.

T. Giese, C. Sommerer, M. Zeier, 2012, Clinica chimica acta; international journal of clinical chemistry.

Educational Attainment Is Associated With Kidney and Cardiovascular Outcomes in the German CKD (GCKD) Cohort

H. U. Zacharias, E. Schaeffner, M. Bergmann, 2022, Kidney international reports.

First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis

D. Swinkels, L. Matis, K. Budde, 2019, PloS one.

AEB071 – a promising immunosuppressive agent

C. Sommerer, M. Zeier, 2009, Clinical transplantation.

Analytical Validation and Cross-Validation of an NFAT-Regulated Gene Expression Assay for Pharmacodynamic Monitoring of Therapy With Calcineurin Inhibitors

T. Giese, C. Sommerer, M. Shipkova, 2016, Therapeutic drug monitoring.

The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen.

C. Sommerer, B. Suwelack, M. Koch, 2012, Transplantation reviews.

Status of periodontal health in German patients suffering from chronic kidney disease - Data from GCKD study.

C. Wanner, K. Eckardt, C. Sommerer, 2019, Journal of clinical periodontology.

Overhydration Is a Strong Predictor of Mortality in Peritoneal Dialysis Patients – Independently of Cardiac Failure

C. Sommerer, M. Zeier, L. Kihm, 2016, PloS one.

Real‐Time Contrast‐Enhanced Sonography of Renal Transplant Recipients Predicts Chronic Allograft Nephropathy

H. Katus, C. Sommerer, M. Zeier, 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.

C. Fitzner, F. Eitner, T. Rauen, 2017, Journal of the American Society of Nephrology : JASN.

After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.

C. Wanner, T. Benzing, F. Artunc, 2020, Kidney international.

Pharmacodynamic Monitoring of Cyclosporin A Reveals Risk of Opportunistic Infections and Malignancies in Renal Transplant Recipients 65 Years and Older

T. Giese, C. Sommerer, M. Zeier, 2011, Therapeutic drug monitoring.

Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.

K. Budde, C. Sommerer, M. Zeier, 2010, British journal of clinical pharmacology.

Ciclosporin A Tapering Monitored by NFAT-Regulated Gene Expression: A New Concept of Individual Immunosuppression

T. Giese, C. Sommerer, M. Zeier, 2008, Transplantation.

Pharmacodynamic immune monitoring of NFAT‐regulated genes predicts skin cancer in elderly long‐term renal transplant recipients

A. Enk, T. Giese, C. Sommerer, 2008, Clinical transplantation.

Sotrastaurin, a Novel Small Molecule Inhibiting Protein Kinase C: First Clinical Results in Renal‐Transplant Recipients

K. Budde, M. Barten, C. Sommerer, 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients

C. Sommerer, M. Zeier, V. Schwenger, 2008, Journal of hypertension.

Color Doppler Indices of Renal Allografts Depend on Vascular Stiffness of the Transplant Recipients

C. Sommerer, M. Zeier, A. Nahm, 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease.

C. Wanner, B. Banas, K. Budde, 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Association of Serum Uromodulin with Death, Cardiovascular Events, and Kidney Failure in CKD.

A. Köttgen, K. Eckardt, C. Sommerer, 2020, Clinical journal of the American Society of Nephrology : CJASN.

Acute phase reaction to gadolinium-DTPA in dialysis patients.

H. Katus, C. Sommerer, M. Zeier, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade

C. Sommerer, M. Zeier, C. Süsal, 2017, Expert opinion on pharmacotherapy.

Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials

F. Lehner, P. Reinke, K. Budde, 2018, BMC Nephrology.

An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.

F. Thaiss, C. Sommerer, D. Dragun, 2019, Kidney international.

Plasma‐Derived C1 Esterase Inhibitor for Acute Antibody‐Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double‐Blind Placebo‐Controlled Pilot Study

R. Montgomery, C. Sommerer, E. Woodle, 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

The extent of HLA‐DR expression on HLA‐DR+ Tregs allows the identification of patients with clinically relevant borderline rejection

C. Sommerer, M. Zeier, S. Meuer, 2013, Transplant international : official journal of the European Society for Organ Transplantation.

An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in denovo kidney transplant patients

F. Thaiss, C. Sommerer, D. Dragun, 2022 .

Cardiac biomarkers are influenced by dialysis characteristics.

H. Katus, C. Sommerer, M. Zeier, 2007, Clinical nephrology.

Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study

F. Kronenberg, A. Köttgen, K. Eckardt, 2019, Clinical Kidney Journal.

High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitis.

C. Sommerer, M. Zeier, M. Schaier, 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The living kidney donor: giving life, avoiding harm.

C. Sommerer, M. Zeier, E. Ritz, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Therapeutic drug monitoring detects high interpatient variability in response to mycophenolic acid treatment in patients with ANCA-associated vasculitis

C. Sommerer, M. Zeier, M. Schaier, 2013 .

Two‐year outcomes in de novo renal transplant recipients receiving everolimus‐facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study

S. Chadban, S. Mulgaonkar, C. Sommerer, 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Synergistic effect of cinacalcet and active vitamin D in a dialysis patient with secondary hyperparathyroidism

C. Karger, C. Sommerer, M. Zeier, 2010 .

Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil.

C. Sommerer, M. Zeier, M. Schaier, 2010, Rheumatology.

Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial

J. D. de Fijter, A. Hartmann, B. Tönshoff, 2008, Transplantation.

Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors.

C. Sommerer, M. Zeier, C. Morath, 2007, Transplantation proceedings.

Immunomonitoring of nuclear factor of activated T cells–regulated gene expression: The first clinical trial in liver allograft recipients

T. Giese, N. Schott, W. Stremmel, 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Living donor kidney transplantation in crossmatch‐positive patients enabled by peritransplant immunoadsorption and anti‐CD20 therapy

C. Sommerer, M. Zeier, S. Macher-Goeppinger, 2012, Transplant international : official journal of the European Society for Organ Transplantation.

Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.

P. Reinke, K. Budde, C. Sommerer, 2015, Clinical nephrology.

Methylprednisolone treatment increases the proportion of the highly suppressive HLA-DR(+)-Treg-cells in transplanted patients.

C. Sommerer, M. Zeier, E. Schmitt, 2012, Transplant immunology.

The role of age‐related T‐cell differentiation in patients with renal replacement therapy

L. Uhlmann, A. Ho, C. Sommerer, 2017, Immunology and cell biology.

Long-term Surgical Outcome and Risk Factors in Living Kidney Donors.

M. Büchler, A. Mehrabi, C. Sommerer, 2020, Transplantation proceedings.

Effect of everolimus‐based drug regimens on CMV‐specific T‐cell functionality after renal transplantation: 12‐month ATHENA subcohort‐study results

F. Lehner, F. Thaiss, C. Sommerer, 2020, European journal of immunology.

Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.

G. Russ, S. Chadban, O. Viklicky, 2019, Transplantation.

Five‐Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study

F. Lehner, F. Lehner, P. Reinke, 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial

P. Reinke, K. Budde, C. Sommerer, 2015, Journal of Nephrology.

Contrast Enhanced Sonography Shows Superior Microvascular Renal Allograft Perfusion in Patients Switched From Cyclosporine A to Everolimus

C. Sommerer, M. Zeier, L. Kihm, 2009, Transplantation.

Incidences of Infectious Events in a Renal Transplant Cohort of the German Center of Infectious Diseases (DZIF)

T. Giese, C. Sommerer, M. Zeier, 2022, Open forum infectious diseases.

Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil RHEUMATOLOGY

C. Sommerer, M. Zeier, M. Schaier, 2010 .

Efficacy and safety of conversion from cyclosporine to everolimus in living‐donor kidney transplant recipients: an analysis from the ZEUS study

F. Lehner, P. Reinke, K. Budde, 2014, Transplant international : official journal of the European Society for Organ Transplantation.

Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR)

F. Lehner, K. Budde, C. Sommerer, 2019, PloS one.

The influence of immunosuppression on the development of BK virus nephropathy-- does it matter?

C. Sommerer, M. Zeier, J. Beimler, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients

K. Budde, C. Sommerer, B. Hartmann, 2010, Therapeutic drug monitoring.

Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography

W. März, M. Kleber, H. Scharnagl, 2019, Scientific Reports.

Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients.

G. Russ, S. Chadban, C. Sommerer, 2019, Transplantation reviews.

Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study

S. Chadban, C. Sommerer, J. Pascual, 2021, BMJ Open.

Everolimus immunosuppression in kidney transplantation: What is the optimal strategy?

C. Sommerer, W. Arns, O. Witzke, 2016, Transplantation reviews.

Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients

K. Budde, C. Sommerer, W. Arns, 2011, Transplantation.

Increased Cyclosporin A Sensitivity In Vivo in Pediatric Renal Transplant Recipients Compared With Adults

T. Giese, B. Tönshoff, C. Sommerer, 2012, Therapeutic drug monitoring.

A need-adapted transition program after pediatric kidney transplantation

B. Tönshoff, C. Sommerer, M. Zeier, 2019, Journal of Transition Medicine.

Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial

A. Mehrabi, C. Sommerer, M. Zeier, 2022, BMJ Open.

Outcomes and complications following ABO‐incompatible kidney transplantation performed after desensitization by semi‐selective immunoadsorption ‐ a retrospective study

A. Mehrabi, C. Sommerer, M. Zeier, 2019, Transplant international : official journal of the European Society for Organ Transplantation.

Current pharmacotherapeutical options for the prevention of kidney transplant rejection

C. Sommerer, M. Zeier, C. Süsal, 2013, Expert opinion on pharmacotherapy.

Reporting Quality-of-Life Outcomes in Clinical Trials of Immunosuppressive Therapy in Kidney Transplantation.

C. Sommerer, M. Zeier, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Reduced residual gene expression of nuclear factor of activated T cells‐regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation

T. Giese, W. Stremmel, C. Sommerer, 2014, Transplant infectious disease : an official journal of the Transplantation Society.

Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit?

T. Giese, C. Sommerer, M. Zeier, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Pharmacodynamic Monitoring of Cyclosporine A in Renal Allograft Recipients Shows a Quantitative Relationship Between Immunosuppression and the Occurrence of Recurrent Infections and Malignancies

T. Giese, C. Sommerer, M. Zeier, 2006, Transplantation.

Should kidney allografts from old donors be allocated only to old recipients?

B. Tönshoff, L. Rostaing, O. Viklicky, 2020, Transplant international : official journal of the European Society for Organ Transplantation.

Monitoring of gene expression in tacrolimus‐treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study

T. Giese, K. Budde, C. Sommerer, 2021, British journal of clinical pharmacology.

Mutations in the BC‐loop of the BKV VP1 region do not influence viral load in renal transplant patients

C. Sommerer, M. Zeier, P. Schnitzler, 2009, Journal of medical virology.

Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients

T. Giese, C. Sommerer, M. Zeier, 2021, Vaccines.

High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients

M. Kloor, M. von Knebel Doeberitz, C. Sommerer, 2011, British Journal of Cancer.

Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant Recipients

A. Mehrabi, C. Sommerer, M. Zeier, 2022, Journal of the American Society of Nephrology : JASN.

Phase-I trial of donor-derived modified immune cell infusion in kidney transplantation.

J. Hoheisel, Andrea S Bauer, A. Mehrabi, 2020, The Journal of clinical investigation.

Efficacy and Safety of Three Different Treatment Regimens in de Novo Renal Transplant Patients: Results of the HERAKLES Trial: 1722

F. Lehner, K. Budde, C. Sommerer, 2012 .

The long-term consequences of living-related or unrelated kidney donation.

C. Sommerer, M. Zeier, C. Morath, 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3‐Year Results From the Randomized ZEUS Study

F. Lehner, F. Lehner, P. Reinke, 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

Thomas Becker, Klemens Budde, Petra Reinke, 2011, The Lancet.

Individualized Monitoring of Nuclear Factor of Activated T Cells-Regulated Gene Expression in FK506-Treated Kidney Transplant Recipients

T. Giese, C. Sommerer, M. Zeier, 2010, Transplantation.

Clinical validation of a novel enzyme‐linked immunosorbent spot assay‐based in vitro diagnostic assay to monitor cytomegalovirus‐specific cell‐mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study

B. Banas, R. Wagner, C. Sommerer, 2018, Transplant international : official journal of the European Society for Organ Transplantation.

The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial

T. Giese, G. Rauch, C. Sommerer, 2014, Trials.

Analytical Aspects of the Implementation of Biomarkers in Clinical Transplantation

U. Christians, C. Sommerer, N. Picard, 2016, Therapeutic drug monitoring.

Cyclosporine-induced gingival overgrowth correlates with NFAT-regulated gene expression: a pilot study.

T. Giese, C. Sommerer, M. Zeier, 2011, Journal of clinical periodontology.

Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption

A. Mehrabi, C. Sommerer, M. Zeier, 2018, Frontiers in Medicine.

Urinary miR‐155‐5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation

K. Budde, C. Sommerer, M. Zeier, 2017, British journal of clinical pharmacology.

Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study

C. Sommerer, G. Wolf, C. Jung, 2020, Journal of clinical medicine.

Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.

S. Chadban, S. Mulgaonkar, C. Sommerer, 2018, Journal of the American Society of Nephrology : JASN.

Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study

F. Kronenberg, A. Köttgen, C. Wanner, 2018, PloS one.

New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients.

T. Giese, C. Sommerer, M. Zeier, 2010, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

Pharmacodynamic cyclosporine A‐monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients

T. Giese, H. Katus, C. Sommerer, 2007, Transplant international : official journal of the European Society for Organ Transplantation.

Absence of mismatch repair deficiency-related microsatellite instability in non-melanoma skin cancer.

M. Kloor, C. Sommerer, M. Zeier, 2012, The Journal of investigative dermatology.

Approaches towards Individualized Immune Intervention

T. Giese, C. Sommerer, M. Zeier, 2010, Digestive Diseases.

Monitoring immunosuppression with measures of NFAT decreases cancer incidence.

T. Giese, C. Sommerer, M. Zeier, 2009, Clinical immunology.

Pharmacodynamic Monitoring of Ciclosporin and Tacrolimus: Insights From Nuclear Factor of Activated T-Cell–Regulated Gene Expression in Healthy Volunteers

T. Giese, C. Sommerer, D. Czock, 2022, Therapeutic drug monitoring.

Pharmacodynamic Disparities in Tacrolimus-Treated Patients Developing Cytomegalus Virus Viremia

T. Giese, C. Sommerer, M. Zeier, 2011, Therapeutic drug monitoring.

Activity of nuclear factor of activated T cells is independent of the number of peripheral lymphocytes in FTY720-treated patients.

T. Giese, C. Sommerer, M. Zeier, 2008, Transplantation proceedings.

Soluble Urokinase Receptor and Mortality in Kidney Transplant Recipients

C. Sommerer, M. Zeier, C. Süsal, 2022, Transplant International.

Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease – cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort

F. Kronenberg, W. Gronwald, P. Oefner, 2016, BMC Nephrology.

The German Chronic Kidney Disease (GCKD) study: design and methods.

Hans-Ulrich Prokosch, Olaf Gefeller, Florian Kronenberg, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

KLKB1 and CLSTN2 are associated with HDL-mediated cholesterol efflux capacity in a genome-wide association study.

Hermann W. Haller, F. Kronenberg, W. Gronwald, 2023, Atherosclerosis.

Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV

C. Sommerer, M. Zeier, T. Mertens, 2022, International journal of molecular sciences.

Switch to an everolimus‐facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients

C. Sommerer, M. Zeier, M. Schaier, 2017, Clinical transplantation.

Evaluation of Hepatocyte Growth Factor as a Sensitive Marker for Early Detection of Acute Renal Allograft Rejection

C. Sommerer, M. Zeier, G. Opelz, 2007, Transplantation.

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

C. Fitzner, F. Eitner, T. Rauen, 2015, The New England journal of medicine.

Cyclosporin A Toxicity of the Renal Allograft – a Late Complication and Potentially Reversible

C. Sommerer, M. Zeier, A. Nahm, 2002, Nephron.

Five‐year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low‐exposure cyclosporine versus standard therapy

F. Lehner, P. Reinke, A. Mehrabi, 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Early Conversion From Calcineurin Inhibitor‐ to Everolimus‐Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial

F. Bemelman, C. Sommerer, J. Pascual, 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi

C. Sommerer, M. Zeier, R. Waldherr, 2015, Transplant international : official journal of the European Society for Organ Transplantation.

Henoch-Schönlein purpura in adults is not uncommon in elderly patients with an adverse prognosis.

C. Sommerer, M. Zeier, R. Waldherr, 2011, Clinical nephrology.

Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial.

C. Sommerer, M. Zeier, P. Schnitzler, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation.

K. Budde, C. Sommerer, J. Rovira, 2021, Clinical immunology.

Human Leucocyte Antigen–Matching Can Improve Long Term Outcome of Renal Allografts from Donors Older Than 75 Years

F. Thaiss, K. Lopau, C. Sommerer, 2023, Transplantation Proceedings.

FTY720 Versus Mycophenolate Mofetil in De Novo Renal Transplantation: Six-Month Results of a Double-Blind Study

F. Schena, C. Sommerer, P. Lang, 2007, Transplantation.

Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study

F. Lehner, P. Reinke, K. Budde, 2018, BMC Nephrology.

Effect of mycophenolic acid on inosine monophosphate dehydrogenase (IMPDH) activity in liver transplant patients.

A. Mehrabi, W. Stremmel, C. Sommerer, 2020, Clinics and research in hepatology and gastroenterology.

RENAL FUNCTION, EFFICACY AND SAFETY OF EVEROLIMUS (RAD) / ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) THERAPY AFTER CALCINEURIN INHIBITOR (CNI) WITHDRAWAL IN DE NOVO RENAL TRANSPLANT PATIENTS: FINAL OUTCOMES OF THE ZEUS STUDY: 264

P. Reinke, K. Budde, C. Sommerer, 2008 .

Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial

F. Lehner, P. Reinke, K. Budde, 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.

K. Budde, C. Sommerer, W. Arns, 2010, Clinical journal of the American Society of Nephrology : CJASN.

A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year.

K. Budde, S. Domhan, C. Sommerer, 2013, Clinical nephrology.

Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results

K. Budde, C. Sommerer, O. Witzke, 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

End‐stage renal disease, dialysis, kidney transplantation and their impact on CD4+ T‐cell differentiation

L. Uhlmann, A. Ho, C. Sommerer, 2018, Immunology.

Psychosocial Characteristics of Patients Evaluated for Kidney, Liver, or Heart Transplantation

H. Friederich, C. Sommerer, J. Schultz, 2022, Psychosomatic medicine.

The transplant cohort of the German center for infection research (DZIF Tx-Cohort): study design and baseline characteristics

R. Mikolajczyk, M. Neuenhahn, D. Busch, 2021, European Journal of Epidemiology.

Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients .

T. Giese, C. Sommerer, M. Zeier, 2017, Clinical Nephrology.

CD40 Inhibition with CFZ533 - A New, Fully Human, Non-Depleting, Fc Silent mAB - Improves Renal Allograft Function While Demonstrating Comparable Efficacy vs. Tacrolimus in De-Novo CNI-Free Kidney Transplant Recipients

D. Leeser, S. Mulgaonkar, A. V. van Zuilen, 2018, Transplantation.

TrAnsFOrM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation

S. Chadban, C. Sommerer, J. Pascual, 2014 .

Gender disparity in health-related quality of life and fatigue after living renal donation

C. Sommerer, M. Zeier, N. Metzendorf, 2018, BMC Nephrology.

Psychosocial and physical outcome following kidney donation—a retrospective analysis

G. Rauch, C. Sommerer, M. Zeier, 2015, Transplant international : official journal of the European Society for Organ Transplantation.

Does Borderline Kidney Allograft Rejection Always Require Treatment?

C. Sommerer, M. Zeier, M. Gross, 2010, Transplantation.

Improved Pulse Wave Velocity and Renal Function in Individualized Calcineurin Inhibitor Treatment by Immunomonitoring: The Randomized Controlled Calcineurin Inhibitor-Sparing Trial

T. Giese, C. Sommerer, M. Zeier, 2017, Transplantation.

Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography

W. März, M. Kleber, H. Scharnagl, 2019, Scientific Reports.

Rapid deterioration of renal function in a long-term allograft recipient with recurrent IgA nephritis--is it the only cause?

C. Sommerer, R. Waldherr, C. Morath, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Clinical Manifestation and Management of ADPKD in Western Countries

C. Sommerer, M. Zeier, 2016, Kidney Diseases.

PHARMACOKINETIC AND PHARMACODYNAMIC COMPARISON OF AN INITIALLY INTENSIFIED DOSING REGIMEN VERSUS A STANDARD DOSING REGIMEN OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN RENAL TRANSPLANT PATIENTS.: 717

K. Budde, C. Sommerer, W. Arns, 2008 .

COMPARISON OF AN INITIALLY INTENSIFIED DOSING REGIMEN VERSUS A STANDARD DOSING REGIMEN OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN RENAL TRANSPLANT PATIENTS: EFFICACY AND SAFETY ANALYSIS OF 75 PATIENTS.: 266

C. Sommerer, W. Arns, M. Zeier, 2008 .

Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients

H. Colom, K. Budde, C. Sommerer, 2021, PloS one.

Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion.

A. Mehrabi, C. Sommerer, M. Zeier, 2019, Atherosclerosis Supplements.

Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study

F. Kronenberg, A. Köttgen, C. Wanner, 2018, PloS one.